BeStock  
Markets › Compare › NAMS vs MBX

NAMS vs MBX

Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.

vsvs
NAMS · NewAmsterdam Pharma$18.41 ▼ 5.64%
MBX · MBX Biosciences$49.55 ▼ 7.23%

One year, rebased to 100

Each line starts at 100 so growth is directly comparable

3686137187237Nov 24, '25May 26, '26Nov 20, '26
  • NAMS -53.2%
  • MBX +58.6%

Head to head

MetricNAMSMBX
Price$18.41$49.55
Change today▼ 5.64%▼ 7.23%
Market cap$2.21B$2.46B
Return, 3 months-31.4%-25.4%
Return, year to date-47.5%+57.1%
Return, 1 year-51.9%+83.0%
P/E (TTM)––
P/B3.55.2
P/E percentile vs own 5y27th26th
Dividend yield––
Revenue growth (YoY, latest qtr)+5,406.9%–
Net profit growth (YoY)+75.9%-188.7%
Gross margin––
Operating margin-900.1%–
Net margin-789.9%–
Return on equity-30.2%-33.7%
Analyst target vs. price+195.7%+98.4%
Analyst buy share100%100%
RSI (14)3841
30-day volatility64.1%66.3%
Max drawdown, 1 year-55.6%-37.6%
Trend readStrong downtrendLeaning bearish
Analyst consensusBuyBuy

Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.

What the numbers say

  • MBX is the largest of the group by market value.
  • MBX has returned the most over the past year.
  • NAMS has been the calmest stock over the last 30 days.

Go deeper

Scroll to Top